Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

维亚生物科技控股集团
VIVA BIOTECH HOLDINGS

(Incorporated in the Cayman Islands as an exempted company with limited liability)

(Stock code: 1873)

UPDATE ANNOUNCEMENT REGARDING DEEMED DISPOSAL AND DISPOSAL OF EQUITY INTEREST IN VIVA SHANGHAI

Reference is made to the Company's announcement dated June 11, 2023, July 27, 2023, November 20, 2023 and December 15, 2023 and the circular dated August 9, 2023 (the "**Deemed Disposal Circular**") regarding the deemed disposal and disposal of the Company's interest in VIVA Shanghai to certain institutional investors in 2023. Unless otherwise defined, capitalized terms in this announcement shall have the same meaning as used in the Deemed Disposal Circular.

Pursuant to the Shareholders Agreement, the Viva Shanghai Investors (as defined below) have a right and shall demand VIVA Shanghai, Viva Biotech and the Company (together, the "**Obligors**") to repurchase the equity interest held by them in the event that, amongst others, VIVA Shanghai fails to complete the Qualified IPO or achieve a qualified merger and acquisition transaction on or before December 31, 2026.

On January 5, 2026, the Company received a declaration letter from each of HLC SPV, Qingdao Hongyi, Daxue Investments and True Light P and Raed Capital Holdings 2 Ltd (the "**Viva Shanghai Investors**"), irrevocably agree that they would temporarily suspend their right to require the Obligors to repurchase their equity interest in VIVA Shanghai pursuant to the Repurchase Obligation during any time between December 31, 2026 and December 31, 2028, and that they will not assert their rights relating to the Repurchase Obligation in any manner during this period. There have been no amendments to the Shareholders Agreement and all other terms of the Shareholders Agreement will continue to remain effective, all obligations under the Shareholders Agreement will continue to accrue during such period.

The Shanghai VIVA Investors have informed the Company that they have entered into the undertaking letter considering the prevailing market conditions, latest development of Shanghai VIVA, including its business and capital raising plans, and demonstrates the Shanghai VIVA Investors' confidence in the business of Shanghai VIVA as well as belief that they could continue to realize their investment purpose notwithstanding the temporary suspension of their rights to enforce the Repurchase Obligations.

The Company will publish further update announcements in relation to the future plans of Shanghai VIVA or the Repurchase Obligations as and when appropriate.

By order of the Board
Viva Biotech Holdings
Mao Chen Cheney
Chairman and Chief Executive Officer

Hong Kong, January 5, 2026

As at the date of this announcement, the Board comprises three Executive Directors, namely, Mr. Mao Chen Cheney (Chairman), Mr. Wu Ying and Mr. Ren Delin; two Non-executive Directors, namely, Mr. Wu Yuting and Mr. Wang Stephen Hui; and three Independent Non-executive Directors, namely, Mr. Fu Lei, Ms. Li Xiangrong and Mr. Wang Haiguang.